PharmAust has kicked-off its highly-anticipated Phase I clinical trials for its flagship anti-cancer drug Monepantel in dogs using the first batch of 2000 tablets manufactured to its new and better-tasting formulation. The initial component of the trial is designed to validate the performance of the drug in different dietary settings that dogs may encounter at home. First results are expected in the middle of March this year.
Related Data & Insights
-
-
Rank Company Revenue 128th PharmAust $3.8m 137th Adisyn $2.9m 138th rent.com.au $2.8m 141st Douugh $2.5m 142nd Hazer Group $2.4m 201 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Data & Insights
Mentioned Organisations
Related Articles
24 Apr 2024
Board Moves, April 24 2024
23 Apr 2024
PharmAust CEO resigns
05 Feb 2024
Board Moves February 5, 2024
28 Aug 2023
Board Moves August 28, 2023
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX